Monte Rosa Therapeutics (GLUE) Consolidated Net Income (2020 - 2026)

Monte Rosa Therapeutics' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$44.5 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 194.92% year-over-year to -$44.5 million; the TTM figure through Mar 2026 stood at -$113.4 million (down 1942.48% YoY), while the FY2025 annual figure was -$22.0 million, up 69.77% from the prior year.
• Consolidated Net Income was -$44.5 million for Q1 2026 at Monte Rosa Therapeutics, down from -$29.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $46.9 million in Q1 2025 to a low of -$44.5 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$22.5 million across 5 years, with a median of -$29.5 million in 2025.
• Biggest YoY gain for Consolidated Net Income was 246.66% in 2025; the steepest drop was 319.46% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$30.8 million in 2022, then decreased by 8.02% to -$33.3 million in 2023, then surged by 140.41% to $13.4 million in 2024, then plunged by 319.46% to -$29.5 million in 2025, then slumped by 50.91% to -$44.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$44.5 million (Q1 2026), -$29.5 million (Q4 2025), and -$27.1 million (Q3 2025), per Business Quant data.